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In implementing quality-of-life (QL) endpoints in cancer clinical
trials, the plea for practical measures has become commonplace.
The Australian New Zealand Breast Cancer Trials Group
(ANZBCTG) and the International Breast Cancer Study Group
(IBCSG) use a limited set of patient-rated indicators for assessing
the impact of chemo- and endocrine therapy on QL in breast
cancer clinical trials. These are single-item measures in the linear
analogue self-assessment (LASA) format (Priestman and Baum,
1976), also known in social sciences as visual analogue scales
(VAS). 
The advantages of simple LASA indicators for data collection
are clear-cut. However, these measures are generally expected to
have lower reliability (i.e., less statistical precision) than sound
multi-item measures (McHorney et al, 1992), resulting in lower
responsiveness. For example, in an extensive investigation of a
LASA indicator for mood (Hürny et al, 1996a), the coarse indi-
cator was less efficient than the multi-item reference scale for
detection of chemotherapy side-effects, especially in situations
with a low impact, such as completion of chemotherapy. 
It is less recognized that, in particular situations, single-item
scales may be as efficient as multi-item scales. In the study cited
above, the responsiveness of the indicator increased with the
subjective impact of the clinical event and even exceeded that of
the multi-item scale in case of disease recurrence (i.e., a major
event) (Hürny et al, 1996a). The indicator was probably more
influenced by factors other than mood related to the event,
whereas the multi-item scale, assessing mood more precisely, was
less subject to such influences. In other words, the impaired
discriminant validity of the indicator was associated with an
increased responsiveness. Discriminant validity of a measure
refers to a higher correlation between this measure and the
concepts intended to be measured than those not intended to be
measured. Responsiveness to chemotherapy and course of disease
are key criteria for clinical validity. 
To further investigate the relationship between discriminant
validity and responsiveness of these indicators, we compared them
with standard measures of mental well-being and psychosocial
functioning in patients with early breast cancer. Our hypothesis
was that global single-item indicators are less precise for specific
treatment effects (i.e., less discriminant validity) than multi-item
scales but similarly efficient for overall treatment comparisons
and changes over time because they reflect the summation of the
individual meaning and importance of various factors for each
patient. 
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Summary We investigated the hypothesis that global single-item quality-of-life indicators are less precise for specific treatment effects
(discriminant validity) than multi-item scales but similarly efficient for overall treatment comparisons and changes over time (responsiveness)
because they reflect the summation of the individual meaning and importance of various factors. Linear analogue self-assessment (LASA)
indicators for physical well-being, mood and coping were compared with the Hospital Anxiety and Depression Scale (HAD), the Mood
Adjective Check List (MACL) and the emotional behaviour and social interaction scales of the Sickness Impact Profile (SIP) in 84 patients with
early breast cancer receiving adjuvant therapy. Discriminant validity was investigated by multitrait-multimethod correlation, responsiveness by
standardized response mean (SRM). Discriminant validity of the indicators was present at baseline but less under treatment. Responsiveness
was demonstrated by the expected pattern among treatments (P = 0.008). In patients without chemotherapy, the SRMs indicated moderate
(0.5–0.8) to large (>0.8) improvements in physical well-being (0.70), coping (0.92), HAD anxiety (0.89) and depression (1.19), and MACL
mental well-being (0.68). In patients with chemotherapy for the first 3 months, small but clinically significant improvements (>).2) included
mood (0.38), coping (0.41), HAD axiety (0.31) and MACL mental well-being (0.35). Patients with 6 months chemotherapy showed no
changes. The indicators also reflected mood disorders (HAD) and marked psychosocial dysfunction (SIP) at baseline and under treatment
according to pre-defined cut-off levels. Global indicators were confirmed to be efficient for evaluating treatments overall and changes over
time. The lower reliability of single as opposed to multi-item scales affects primarily their discriminant validity. This is less decisive in large
sample sizes. © 2001 Cancer Research Campaign http://www.bjcancer.com
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PATIENTS AND METHODS 
Sample 
This study included a consecutive sample of patients with operable
breast cancer from Sahlgrenska University Hospital in Göteborg
which were randomized into one of the following IBCSG adjuvant
therapy trials: Trial VI, for pre- and peri-menopausal, node-
positive (N+) patients; Trial VII, for postmenopausal N+ patients;
Trial VIII, for pre- and peri-menopausal, node-negative (N–)
patients; Trial IX, for postmenopausal N-patients. In these trials,
varying schedules of chemotherapy, endocrine therapy and their
combinations were studied. The chemotherapy consisted of 
CMF (cyclophosphamide, methotrexate and 5-fluorouricil); the
endocrine therapy was Tamoxifen or LH-RH (luteinizing
hormone-releasing hormone) analogue. In patients with conserva-
tive surgery (quadrantectomy or lumpectomy) radiotherapy was
started 2 weeks after the last chemotherapy course, or within 3
months in case of endocrine therapy alone. The randomization in
Trials VI and VII was stratified by institution, type of surgery and
oestrogen receptor (ER) status. The randomization in Trials VIII
and IX was stratified by institution, ER status and radiotherapy. 
Trials VI and VII started in July 1986 and were closed in April
1993 (Hürny et al, 1996b), (International Breast Cancer Study
Group, 1996, 1997). Trial VIII started in March 1990 and was
closed in October 1999. Trial IX started in October 1988 and 
was closed in August 1999. For this investigation, patients were
enrolled between April 4, 1990, and November 27, 1992. Patient
characteristics of the study sample were compared with those of
all patients randomized into Trials VI to IX in Sweden between
July 22, 1986 and November 24, 1993 (total Swedish sample). 
Data collection procedure 
Patients were approached by a research nurse within 6 weeks after
primary surgery and after being randomized into 1 of the 4 IBCSG
trials but before starting adjuvant treatment. Besides the IBCSG QL
form assessed in hospital, those patients who agreed to participate in
this study were asked to fill in a set of additional questionnaires at
home and to send it back to the local data manager. Both the
IBCSG QL form and the additional questionnaires were assessed
at baseline and at months 3 and 6 of adjuvant therapy. Clinical and
sociodemographic data were part of the documentation of the
IBCSG trials. 
Indicator and standard measures 
4 LASA indicators were incorporated in the IBCSG QL form:
physical well-being (PWB) (Priestman and Baum, 1976), mood
(Priestman and Baum, 1976; Hürny et al, 1996a) and effort to cope
(PACIS) (Hürny et al, 1993) were designed as global indicators,
appetite as a more specific indicator for cytotoxic side-effects
(Bernhard et al, 1997). All indicators were scored by measuring in
millimetres from 0 to 100 and were reversed, with higher numbers
reflecting better QL (e.g., less effort to cope). Concurrent validity
(Butow et al, 1991), test–retest-reliability (Coates et al, 1990) and
responsiveness to chemotherapy (Hürny et al 1992) have previ-
ously been documented. A 28-item adjective checklist for
emotional well-being (Bf-S) (Zerseen, 1986) was also included in
the IBCSG QL form. The Bf-S was transformed into scores from
0 to 100, with higher numbers reflecting better emotional 
well-being. In clinical trials, the global indicators were particularly
relevant endpoints (Coates et al, 1987; Hürny et al, 1996b;
Bernhard et al, 1999b). We capitalize on this experience. 
To target the broad construct of psychosocial adaptation, we
selected different domains. Mental well-being was measured by
the Mood Adjective Check List (MACL) (Sjöberg et al, 1979). It
contains 71 adjectives which are aggregated into 6 bipolar dimen-
sions: pleasantness/unpleasantness, activation/deactivation, calm-
ness/tension, extraversion/introversion, positive/negative social
orientation and control/lack of control. Each dimension and an
overall score (MACL TOT) is scored from 1 to 4, with higher
numbers reflecting better mood. In various chronic conditions, the
first 3 dimensions were of particular clinical relevance (Sullivan 
et al, 1993). We capitalize on this experience. 
The Hospital Anxiety and Depression Scale (HAD) (Zigmond
and Snaith, 1983) was used as a complement to the MACL. The
HAD contains 14 items which are aggregated into summary scores
for anxiety and depression ranging each from 0 to 21, with higher
numbers reflecting more mood disturbance. The validated classifi-
cation of psychiatric morbidity regarding non-psychiatric cases
(scores 0–7), possible cases (scores 8–10) and probable cases
(scores 11–21) was also tested for the Swedish version in patients
with chronic disease or injury (Sullivan et al, 1993). We used a
dichotomization with the cut-off score of ³8. 
Emotional behaviour (EB) and social interaction (SI), the main
psychosocial dimensions of the Sickness Impact Profile (SIP)
(Bergner et al, 1981), were chosen to assess health-related
dysfunction in personal and social life (Ahlmén et al, 1990;
Sullivan et al, 1993). The SIP/EB contains 9 statements indicative
of depression, anxiety, low self-esteem and lack of control, the
SIP/SI includes 20 statements on quality and quantity of social
interaction within and outside the family. For each dimension, the
percentage of maximum dysfunction is calculated according to
predetermined weights, ranging from 0 to 100 (most dysfunction).
Based on experiences in Sweden (Sullivan et al, 1986), limits for
no (score = 0), slight to moderate (scores 1–10) and marked
dysfunction (scores 11–100) were defined (Augustinsson et al,
1989). We used a dichotomization with the cut-off score of ³11. 
Statistical methods 
Submission rates of the IBCSG QL form including the indicator
measures and of the questionnaires including the comparison
measures were calculated as the ratio of numbers of received
versus expected questionnaires of all patients randomized in the
participating hospital during the study period separately for each
time point. 
Convergent and discriminant validity of the indicators were
investigated by a multitrait-multimethod correlation analysis
(Ahlmén et al, 1990; Sullivan et al, 1993), created from hypo-
theses about measures targeting the same (convergent) versus
different concepts (discriminant validity). A matrix was developed
for baseline and month 6. Correlation coefficients were considered
low (<0.4), moderate-to-high (0.4–0.7) and substantial (>0.7)
(Ware et al, 1993). 
Responsiveness to chemotherapy and changes over time were
tested by standardized response mean (SRM; mean change/SD of
this change) (Liang et al, 1990; Katz et al, 1992). Randomized
treatment assignments were grouped across the whole study
sample separately for the first 3 and 6 months on study as shown in
Table 1. Chemo-endocrine therapy was grouped together with1158 J Bernhard et al 
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chemotherapy. The SRMs were interpreted as trivial (<0.2), small
(0.2–0.5), moderate (0.5–0.8) or large (>0.8) effect size (Cohen,
1977). We used Cohen’s criteria as an illustrative measure and
compared its threshold for a small effect to a minimal clinically
significant change as defined in an adjuvant breast cancer trial
using the same indicators (Hürny et al, 1996b). 
We expected a substantial improvement in QL in patients with
endocrine therapy only reflecting adaptation to disease, to a lesser
extent in those with chemotherapy for the first 3 months reflecting
treatment burden and no improvement in case of chemotherapy for
the first 6 months (Hürny et al, 1996a; 1996b; Bernhard et al,
1997). Among the indicators, adaptation was expected to be most
expressed in coping (PACIS) scores, chemotherapy sides-effects in
coping and physical well-being. The 6-months grouping was
selected as primary comparison and tested across all measures by
the Friedman test. This test is related only to the pattern and there-
fore robust against variation of the single measurements. A sample
size of n = 70 was considered as sufficient. 
As a further issue of clinical validity, we explored whether the
indicators are sensitive to subgroups of patients according to their
levels of mental well-being and psychosocial functioning. The
HAD and SIP scores were chosen as criterion measures. 
Known-groups comparisons of the dichotomized absolute scores
were used at baseline and at month 6. Lines indicating 95% CI
around observed mean effects were chosen to show the consis-
tency of patterns. 
RESULTS 
Sample description and baseline scores 
During the study period, 101 patients were randomized into
IBCSG Trials VI to IX at the Sahlgrenska University Hospital and
were asked to participate in this additional investigation. 88 of
these patients (87%) agreed but 4 were ineligible for the IBCSG
trials. In the remaining sample (n = 84), the submission rate of
both the IBCSG QL form including the indicators and the set
including the comparison measures was 96% at baseline, 90% at
month 3 and 89% at month 6. At each timepoint, the sample size
was varying by QL measure due to missing data on available
questionnaires (LASA indicators: 0–3%, Bf-S: 4–13%, compar-
ison measures: 0–2% by measure and timepoint). 
Biomedical and sociodemographic characteristics of the study
sample and of the total Swedish sample are summarized in Table
Table 1 Biomedical and sociodemographic characteristics of the study sample and the total Swedish sample 
Characteristics Study sample  Total Swedish sample
(n = 84)  (n = 611) 
n % n % 
Menopausal status 
Premenopausal 39 46 281 46 
Postmenopausal 45 54 330 54 
Nodal status 
Positive 59 70 505 83 
Negative 25 30 106 17 
Receptor statusa
PR, negative 29 34 231 38 
PR, positive 55 66 370 62 
ER, negative 10 12 133 22 
ER, positive 74 88 472 78 
Type of surgery 
Total mastectomy 47 56 428 70 
Conservative surgery 37 44 181  30 
Adjuvant treatment groupingb
Months 1–3 n.a.
Chemotherapy 42 55
Endocrine therapy 21 28
Chemo and endocrine therapy 13 17 
Months 1–6 n.a. 
Chemotherapy 3 months 33 45 
Chemotherapy 6 months 19 26 
Endocrine therapy only 21 29 
Partnership 
Yes 57 68 449 74 
No 27 32 159 26 
Employment 
Yes 53 63 399 65 
No 31 37 210 35 
Level of education 
Mandatory 39 46 316 52 
Higher level 45 54 292 48 
a PR: progesterone receptor; ER: estrogen receptor. b Combined groups of randomized treatment groups are applicable to the study
sample only.Clinical relevance of global indicators 1159
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1. The study sample included 84 patients, with a mean age of 56
years (range: 31–75 years); the total sample included 611
patients of the same age (mean = 56 years, range: 28–79 years).
The study sample had a higher rate of patients with conserva-
tive surgery, N– and ER+ status. A similar and unremarkable
sociodemographic situation of both samples was noted compared
with official statistics of Sweden, except a lower percentage of
employment. Overall, the study sample was comparable to the
total sample. 
A majority of patients in the study sample underwent
chemotherapy during the first 6 months on study. 11% of all
patients started radiotherapy before month 3, and 21% between
months 3 and 6. No case of disease recurrence was registered
within the first 6 months. 
The baseline scores of the indicators are shown in Table 2. The
2 samples showed comparable scores. A tendency toward higher
scores (i.e., better QL) was present in all indicators. Overall, the
mood and coping scores were most impaired. 
Convergent and discriminant validity 
The multitrait-multimethod matrix is shown for the scores at
baseline and month 6 in Table 3. Measures targeting the same
(convergent) versus different concepts (discriminant validity)
were investigated both within the indicators and standard
measures and among all measures. It has to be noted that conver-
gent measures included in the same questionnaire are generally
expected to be more highly correlated than those of separate ques-
tionnaires. 
Regarding the indicators at baseline, the 2 measures of
emotional well-being (mood, Bf-S) showed the highest correla-
tion (r = 0.72). The PACIS was moderately related to both phys-
ical and emotional measures (0.42–0.62), thus referring to a
separate construct. Among the standard measures, emotional
scales of different instruments (MACL subscales, HAD anxiety
and depression, SIP emotional behaviour) were closer correlated
with each other (0.38–0.76) than with SIP social interaction
(0.29–0.53). 
Taking into account both indicator and standard measures at
baseline, the mood indicator was most strongly correlated with the
MACL pleasantness (r = 0.77) and total score (r = 0.71) and with
HAD depression (r = 0.69). The complementary adjective 
checklist Bf-S reflected the same pattern with more substantial
correlations. The indicators for coping (0.53–0.65) and physical
well-being (0.42–0.62) showed lower correlations with the 
mental well-being measures than the mood indicator (0.61–0.77),
and they were more highly correlated with mental well-being and
emotional functioning than with social functioning; SIP social
interaction was only marginally associated. 
The matrix at month 6 is based on scores from patients with
different adjuvant treatments. The correlation coefficients were
not adjusted for treatment group to investigate discriminant
validity under treatment overall. Among the indicators, mood and
Bf-S were both strongly correlated with physical well-being (r =
0.80 and 0.78, respectively). Coping was again moderately corre-
lated with both physical and emotional measures (0.48–0.62).
Among the standard measures, emotional scales of different
instruments (MACL subscales, HAD anxiety and depression, SIP
emotional behaviour) were again closer correlated with each other
(0.48–0.84) than with SIP social interaction (0.43–0.66). The coef-
ficients between corresponding indicator and standard measures
were generally lower than at baseline. The mood indicator was
again most but only moderately correlated with the MACL pleas-
antness (r = 0.61) and total score (r = 0.60) and showed the same
pattern of relationships as the Bf-S. Coping was again more highly
correlated with mental well-being and emotional functioning
(0.52–0.63) than it was with SIP social interaction (r = 0.45).
Physical well-being showed a similar pattern, despite the high
correlation with mood. 
In summary, the correlation analyses at baseline showed
convergent and discriminant patterns among the indicator and
standard measures in accordance with their construct. In contrast
to the standard measures, the patterns among the indicators
showed less discriminant validity under treatment than at base-
line. 
Responsiveness to chemotherapy and changes over
time 
Responsiveness of the indicators and the mental well-being
measures to chemotherapy and changes over time were evaluated
over the first 3 and 6 months from randomization. The mood indi-
cator provided reference data for a minimal clinically significant
change. In IBCSG Trial VII, postmenopausal patients who did not
Table 2 Mean values of the QL indicators in the study sample and the total Swedish sample at baseline by menopausal status 
QL indicatorsa Study sample Total Swedish sample 
Menopausal status n Mean (Cl, 95%)  n Mean (Cl, 95%) 
Physical well-being pre 37 70.0 (61.6–78.5) 248 71.0 (68.1–74.0) 
post 41 65.8 (57.5–74.1) 255  69.3 (66.3–72.3) 
Appetite pre 37 76.2 (67.1–85.4)  248 79.3 (76.4–82.2) 
post 41 78.4 (71.3–85.6) 256  78.3 (75.3–81.2) 
Mood pre 37 57.4 (48.6–66.3) 248 59.7 (56.6–62.8) 
post 41 64.0 (56.1–71.9) 255  62.1 (59.1–65.0) 
PACIS pre 37 58.6 (49.0–68.2) 245 56.1 (52.8–59.5) 
post 40 59.2 (49.7–68.6) 252  61.1 (58.0–64.2) 
Bf-S pre 36 69.5 (61.2–77.9) 236 68.2(65.2–71.3) 
post 39 72.3 (65.0–79.5) 244  71.7 (68.9–74.5) 
aAll scales range from 0 to 100, with higher scores indicating better QL.1160 J Bernhard et al 
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receive prior chemotherapy indicated an average within-patient
deterioration of 3.6% of full scale range (i.e., 0–100; P = 0.05) at
the beginning of delayed chemotherapy (Hürny et al, 1996b). This
effect corresponds to a SRM of 0.14 in the group without early
chemotherapy and to 0.18 in that with chemotherapy for 6 months.
It is close to the threshold value of 0.2 for a small effect (Figures 1
and 2). The group with chemotherapy included different treatment
schedules and the number of patients in each group was small.
Therefore, only the main effects are to be interpreted. 
For the 3-months comparison, the 4 indicators were compared
with the HAD anxiety and depression scales, the MACL pleasant-
ness, activity and calmness scales and the MACL total score. This
comparison included patients receiving chemotherapy (with or
without endocrine therapy) versus endocrine therapy only for the
first 3 months. 
Figure 1 shows the SRMs separately for each measure and
treatment group between baseline and month 3. In patients with
no early chemotherapy, the SRM indicated the expected
improvement in all measures of at least moderate degree, with
the exceptions of appetite (0.01) and MACL activity (0.35).
Large effects were present for coping (1.33) and MACL pleas-
antness (0.80). In patients with chemotherapy in this period, the
SRM indicated a small improvement in mood (0.31), coping
(0.21), MACL pleasantness (0.27), calmness (0.37) and total
score (0.27). Physical well-being did not change and differed
from emotional measures, in agreement with the MACL activity
PWB
Appetite
Mood
PACIS
HAD Anxiety
HAD Depress
MACL Pleas
MACL Activ
MACL Calm
MACL TOT
0.2 0.5 0.8
SRM  chemo
SRM no chemo
Figure 1 Standardized response means (SRM) for indicator and standard comparison measures by treatment group between baseline and month 3. SRM are
considered trivial (<0.2), small (0.2–0.5), moderate (0.5–0.8) and large (>0.8). Positive values indicate an improvement 
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HAD Anxiety
HAD Depress
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Figure 2 Standardized response means (SRM) for selected indicator and standard comparison measures by treatment group between baseline and month 6.
SRM are considered trivial (<0.2), small (0.2–0.5), moderate (0.5–0.8) and large (>0.8). Positive values indicate an improvement scale. The coping indicator was most responsive to the presence
or absence of chemotherapy, followed by physical well-being
and the HAD depression scale. 
For the 6-months comparison, we selected those measures with
an SRM of at least moderate degree in either group of the 3-
months comparison. This comparison included patients receiving
chemotherapy (with or without endocrine therapy) for 6 months
versus chemotherapy (with or without endocrine therapy) for the
first 3 months versus endocrine therapy only for the first 6 months. 
Figure 2 shows the SRMs separately for the selected measures
and the 3 treatment groups between baseline and month 6. In
patients with no early chemotherapy, the SRM showed the
expected improvement of moderate to large degree in all
measures, with the exception of mood (SRM = 0.35). In patients
with chemotherapy for the first 3 months, the SRM indicated a
similar pattern of a small improvement as in the 3 month period,
with comparable responsiveness of the indicators for mood (0.38)
and coping (0.41), the MACL pleasantness (0.37), calmness (0.46)
and total score (0.35), and HAD anxiety (0.31). In patients with
chemotherapy for 6 months, the SRM were again smaller, with the
exception of mood (0.49), indicating no or only small changes.
The only and small deterioration relative to baseline was noted for
MACL calmness (–0.23). The latter scale was most responsive to
the distinction between 3 and 6 months of chemotherapy, followed
by MACL pleasantness and HAD anxiety. The predicted
dose–response pattern was present both for the standard measures
(HAD anxiety, MACL) and the indicators (physical well-being,
coping) (P = 0.008). 
In summary, the indicators reflected the presence or absence of
early chemotherapy at least as well as the standard measures but
were less sensitive to the duration of chemotherapy. 
Distinguishing groups by levels of mental distress and
psychosocial dysfunction 
The indicators’ responsiveness to clinically validated levels of
mental distress and psychosocial dysfunction (i.e., ‘case’ versus
‘non-case’) was investigated for scores at baseline and month 6.
The evaluation at month 6 was based on absolute scores without
adjustment for baseline or treatment. 
Figure 3 shows the indicator scores according to HAD anxiety
(non-cases n = 54; cases: n = 27) and depression (non-cases n =
74; cases: n = 7) at baseline. All of the indicators reflected the
presence or absence of a possible or probable mood disorder in the
expected direction. The only marked overlap of confidence inter-
vals regarding non-cases and cases was in the prediction of phys-
ical well-being by depression, the number of cases being at the
lower limit for this type of illustration. The distinction was most
pronounced for mood and coping. Patients with anxiety beyond
the cut-off level reported a similar level of mood (mean = 43) and
coping (mean = 37) which was remarkably lower compared to
that of the non-cases (mood: mean = 71; coping: mean = 68).
Depression yielded similar figures, with low levels in cases
(mood: mean = 28; coping: mean = 30) and substantially higher
levels in non-cases (mood: mean = 65; coping: mean = 61). 
Figure 4 shows the indicator scores according to SIP emotional
behaviour (non-cases = no or slight-to-moderate dysfunction: n =
56; cases = marked dysfunction: n = 25) and social interaction
(non-cases: n = 67; cases: n = 14) at baseline. Regarding emotional
behaviour, all of the indicators reflected the presence or absence of
dysfunction in the expected direction. Mood and coping were
again most sensitive. Cases with marked emotional dysfunction
reported a low level of mood (mean = 47) and coping (mean = 42)
1162 J Bernhard et al 
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Figure 3 Mean scores with 95% Cl of the indicator measures by HAD anxiety and depression at baseline. For each indicator, scores of non-psychiatric cases
according to the HAD criterion measure are shown as first line, scores of possible and probable cases as second line. Higher scores of the indicators refer to
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which clearly contrasted to that of the non-cases (mood: mean = 68;
coping: mean = 65). There were similar findings regarding social
interaction (SIP), with some overlap of confidence intervals in
physical well-being, mood and coping probably due to the small
number of cases. 
At month 6, the findings were consistent with those at baseline.
All of the indicators reflected the absence (n = 54) or presence 
(n = 21) of anxiety (HAD) and the absence (n = 58) or presence
(n = 17) of marked emotional dysfunction (SIP), with the largest
differences again for mood and coping. There was some overlap of
confidence intervals in all indicators regarding non-cases (n = 68)
and cases (n = 7) of depression (HAD) and non-cases (n = 63) and
cases (n = 12) of marked social dysfunction (data not shown). 
DISCUSSION 
In a consecutive Swedish sample of patients with early breast
cancer, we investigated the hypothesis that global QL indicators
assessed with single items have less discriminant validity and thus
are less precise for specific treatment effects than multi-item scales
but similarly efficient for overall treatment comparisons and
changes over time. 
The standard measures indicated the expected impairment in
this situation (Fallowfield et al, 1990; Maunsell et al, 1996), char-
acterized by anxiety rather than depression (Maraste et al, 1992).
At baseline, the indicators and standard measures showed conver-
gent and discriminant patterns in accordance with their concept.
For example, the mood indicator yielded the same pattern with the
standard measures as the adjective checklist for emotional well-
being (Bf-S) but showed lower correlations in consequence of its
lower reliability. 
Under treatment, these patterns were less convergent or discrim-
inant as compared to baseline. In particular, mood and physical
well-being were substantially correlated. Obviously, the indicator
and standard measures were affected differently by the various
treatment regimens. To get an overall impression, we did not
adjust this analysis for treatment. The question is how the lower
discriminant validity of the indicators does affect their responsive-
ness to chemotherapy and changes over time. 
In patients without chemotherapy, both the global indicators and
the standard measures reflected the adaptation to the disease.
Among the indicators this change was most obviously expressed in
perceived coping effort, the most subjective measure (Hürny et al,
1993). This finding speaks for a summative effect of various
factors. 
In patients with 3 months chemotherapy, the responsiveness was
comparable between the indicators for mood and coping and the
MACL pleasantness and calmness scales, whereas the HAD
depression scores were almost stable. As a reflection of treatment
burden, patients receiving chemotherapy for 6 months showed no
improvement. An exception was mood. This indicator and that for
physical well-being showed clearly different patterns despite the
unusually high proportion of variance (64%) explained by each other.
Overall, the standard measures reflected the distinction between
3 and 6 months of chemotherapy better than the indicators.
However, in regard to the more sharply contrasting situations of
patients with and without chemotherapy, the indicators showed at
least comparable performance. In other words, their lower dis-
criminant validity did not result in less responsiveness to 2
markedly different clinical situations. 
From a psychometric point of view, the lower precision of the
indicators under treatment questions their validity as outcome
measures. This may be less so from a clinical point of view. It is
common sense that patients’ perception of disease and treatment
burden is more of a global nature than subdivided into highly
specific domains as assessed by the standard measures. The
contributing clinical factors may substantially change over time.
The pattern of response among the indicators speaks again for a
summative effect reflecting the individual meaning and impor-
tance of various factors. 
This property may also explain the responsiveness of the indica-
tors to mental distress and psychosocial dysfunction. All were
0 50 100 / 0 100
LASA indicator scores
PACIS
Appetite
Mood
PWB
SIP Emotional Behavior SIP Social Interaction
Figure 4 Mean scores with 95% Cl of the indicator measures by SIP emotional behaviour and social interaction at baseline. For each indicator, scores of no
more than moderate dysfunction according to the SIP criterion measure are shown as first line, scores of marked dysfunction as second line. Higher scores of
the indicators refer to better QL1164 J Bernhard et al 
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sensitive to these conditions both at baseline and under treatment.
In accordance with their concept, the indicators for mood and
coping were most sensitive. Adjustment to breast cancer is known
to be associated with mental distress and psychiatric morbidity
(Watson et al, 1991), irrespective of any causal interaction.
Physical well-being and appetite also reflected the criterion
measures well. Patients under higher psychological distress are
expected to report more physical symptoms (Watson and
Pennebaker, 1989), as shown in the situation of adjuvant therapy
for breast cancer (Manne et al, 1994). 
Serious psychosocial impairment is only partly determined by
cytotoxic side-effects but influenced by multiple individual factors
such as a history of depression (Maunsell et al, 1992). In case of
relatively mild regimens, as in this study, there is evidence that
adaptation to the disease is more important for patient’s QL than
cytotoxic side-effects (Hürny et al, 1996b). Identifying patients
with poor adaptation is relevant for subgroup analyses, for
example in developing risk-adapted treatment strategies or
supportive interventions. Given the large sample sizes of phase-III
trials, these indicators may carry this type of information suffi-
ciently well. However, the sensitivity of the HAD as screening
instrument has recently been questioned, especially regarding
depression (Hall et al, 1999). Our findings have to be interpreted
within these limitations. 
The evaluation of single-item measures has frequently been
restricted to cross-sectional comparison with standard measures
(McCormack et al, 1988; Cunny and Perri, 1991). McHorney et al
investigated how precisely different methods for measuring
general health status discriminated between different groups of
patients (McHorney et al, 1992). Their results suggested that
roughly twice the sample size would be required for a single-item
measure to achieve the precision of a long-form (multi-item)
measure. A cancer clinical trial is a different situation. Given that
disease and treatment factors may change considerably only a
longitudinal comparison gives sufficient information to judge the
properties of QL measures. 
The rather small sample limits the generalization of our find-
ings, although it was sufficiently large to demonstrate the expected
pattern, in agreement with previous studies in early (Hürny et al,
1996b) and advanced disease (Coates et al, 1987). The sensitivity
to performance status (Bernhard et al, 1999a), disease recurrence
(Hürny et al, 1996b) and tumour response (Bernhard et al, 1999b),
and their prognostic value for survival (Coates et al, 1992, 1993;)
add evidence to the clinical relevance of these indicators. 
In conclusion, LASA indicators were confirmed to be respon-
sive to cytotoxic side effects, mental distress and psychosocial
dysfunction in patients with early breast cancer. According to our
hypothesis, the lower reliability of single as opposed to multi-item
scales affects more their discriminant validity than responsiveness.
This is less decisive for treatment comparisons in large sample
sizes. 
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